文献速递血栓与止血

血栓形成倾向基因突变预测接受化疗的门诊癌症患者静脉血栓栓塞症

Thrombophilia gene mutations predict venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
PubMed 文献 · J Thromb Haemost · 2023-08-02

该研究为AVERT试验的事后分析,纳入447例中高危门诊癌症患者,评估既往已知的血栓形成倾向基因突变与化疗开始后7个月内静脉血栓栓塞症(VTE)或出血的关联。结果显示,凝血因子V Leiden(FVL)突变和非O血型与VTE风险显著增加相关(OR分别为5.2和2.7),预防性抗凝使FVL患者VTE得到完全保护,未抗凝者VTE发生率为每100患者年119例。

要点

  • FVL突变者VTE的OR为5.2(95%CI 1.9-14.7),非O血型者OR为2.7(95%CI 1.2-6.1)。
  • FVL患者使用预防性抗凝后VTE完全保护,未抗凝者VTE率为每100患者年119例。
  • 其他受检血栓形成倾向基因与VTE或出血无显著关联。

核心结论

  • FVL突变和ABO血型可能是开始化疗的癌症患者重要的VTE预测因素。

研究设计与样本

  • AVERT试验的事后分析,使用入组患者的血液样本,共447例中高危门诊癌症患者。
  • 检测既往已知的血栓形成倾向基因突变(凝血酶原FII G20210A、FXI、纤维蛋白原gamma、serpin家族A成员10、FV K858R、FXIII、FVL和ABO血型),观察化疗开始后7个月内的VTE或出血。
  • 采用逻辑回归比较杂合和纯合突变(合并)与野生型。
  • 按预防性抗凝使用分层计算突变患者的VTE率、出血率和风险差。

主要发现

  • 447例患者中共发生39例VTE和39例出血事件。
  • FVL突变者VTE的OR为5.2(95%CI 1.9-14.7),非O血型者VTE的OR为2.7(95%CI 1.2-6.1)。
  • FVL患者使用预防性抗凝后VTE完全保护,未接受抗凝者VTE率为每100患者年119例。
  • 非O血型患者使用预防性抗凝后VTE率也较低。
  • 其他受检血栓形成倾向基因与VTE或出血无显著关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inherited thrombophilia and cancer both independently increase the risk of venous thromboembolism (VTE). However, whether the increased VTE risk associated with inherited thrombophilia exists in cancer patients is less clear. OBJECTIVES: Our objective was to determine the influence of inherited thrombophilia on VTE and bleeding risk in moderate-to-high-risk ambulatory cancer patients receiving chemotherapy. METHODS: We conducted a post hoc analysis using blood samples from patients enrolled in the AVERT trial to determine if previously recognized thrombophilia gene mutations (prothrombin factor [F] II G20210A, FXI, fibrinogen gamma, serpin family A member 10, FV K858R, FXIII, FV Leiden [FVL], and ABO blood) were associated with VTE or bleeding during the 7-months after starting chemotherapy. Logistic regression was used to compare heterozygous and homozygous mutations (combined) to wild-type. VTE rates, bleeding rates, and risk differences for mutations stratified by prophylactic anticoagulation use were calculated. RESULTS: Of the 447 patients, there were 39 VTE and 39 bleeding events. The odds of VTE were significantly increased with FVL mutation and non-O blood type (odds ratio [OR]: 5.2; 95% CI: 1.9-14.7 and OR: 2.7; 95% CI: 1.2-6.1, respectively). The use of anticoagulation prophylaxis resulted in complete protection in FVL patients, whereas those not receiving anticoagulation had a VTE rate of 119 per 100 patient-years. Lower VTE rates were also observed in non-O blood type patients taking prophylactic anticoagulation. No other thrombophilia genes tested were significantly associated with VTE or bleeding. CONCLUSION: Our results indicate that FVL mutation and ABO blood type may be important VTE predictors in cancer patients starting chemotherapy.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Roy DC, Wang TF, Carrier M, et al. Thrombophilia gene mutations predict venous thromboembolism in ambulatory cancer patients receiving chemotherapy. J Thromb Haemost. 2023. PMID: 37536569. doi:10.1016/j.jtha.2023.07.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。